Danatlas Pharmaceuticals Co,Ltd.was established in 2021. It is an innovative and dynamic drug research and development enterprise. Adhering to the development strategy of "rooted in China and facing the world", it takes innovation-driven development as its core and focuses on the development of "first-in-class (FIC)" target drugs in the era of precision oncology 2.0, aiming to meet the clinical needs of patients and promote the innovative development of the medical field. With the grand vision of "becoming a leader in the development of new tumor-targeted therapies", and the mission of "sincerity and dedication" in making innovative drugs, the company is committed to bringing new hope for "reigniting health" to humanity.

The company has a registered capital of 14.28 million yuan and was founded by a leading scientist who returned from abroad. Its founding team, with rich experience in new drug creation and R&D management, has successfully led the launch of several influential innovative drugs, demonstrating outstanding professional capabilities and industry insight. The company is also equipped with a 3,000-square-meter international first-class R&D laboratory and has set up a branch center in Boston, USA, providing a solid hardware foundation and an international exchange platform for drug research and development. Currently, several global first-in-class (FIC) new drug projects of the company are in the R&D stage, and it has submitted 4 PCT international invention patents, highlighting its strong scientific research and innovation capabilities.

In terms of scientific research achievements, on June 18, 2025, the IND application for the company's independently developed DNA polymerase theta (POLQ) inhibitor DAT-1604 was approved by the National Medical Products Administration (NMPA). Previously, this project was approved by the US FDA on April 11, 2025. This achievement marks a major breakthrough for the company in the field of drug research and development and further enhances its reputation and influence in the international pharmaceutical R&D field.

As an innovation-driven company focusing on the research of DNA damage repair (DNA Damage Repair) mechanisms, Danqing Pharmaceutical has built a powerful "First-in-Class & Best-in-Class" tumor precision drug R&D pipeline and advanced technology platform, covering target identification, validation, drug discovery, translational medicine, clinical research, and other high-level professional functions. The company is actively negotiating cooperation with professional institutions dedicated to conquering global breast cancer, gynecological cancers, digestive tract tumors, urinary system tumors, and other solid tumors, aiming to establish extensive strategic partnerships and expecting to bring these transformative products and therapies to the market as soon as possible to benefit more patients.